Comparison

Dihydromyricetin (DHM) vs TUDCA

DHM tackles alcohol metabolism and mild liver stress; TUDCA is the gold standard for cycle-induced hepatotoxicity.

Dihydromyricetin (DHM)

Flavonol / GABA-A Modulator

Supplementt½ ~3.7 hours (oral)

TUDCA

Hepatoprotective Bile Acid

Supplementt½ 1–2 hours (plasma); functional duration ~8–12 hours via enterohepatic recycling

Effectiveness Profile

Dihydromyricetin (DHM)
TUDCA

At a Glance

 Dihydromyricetin (DHM)TUDCA
TypeSupplementSupplement
Legal statusOTCOTC
Half-life~3.7 hours (oral)1–2 hours (plasma); functional duration ~8–12 hours via enterohepatic recycling
Preferred routeOralOral
Dose frequencytwice-dailytwice-daily
Beginner dose300–500 mg250–500 mg
Intermediate dose500–1000 mg500–1000 mg
Advanced dose1000–1800 mg1000–1750 mg
Cycle length1–12 wks4–12 wks
Bioavailability4%45%
Time to peak2.75h1h
Active duration6h10h
StorageRoom temperature, dry, protected from lightRoom temperature, dry, away from light
PCT requiredNoNo
Ancillaries requiredNoNo
Safe for womenYesYes

Verdict

Dihydromyricetin (DHM) wins for acute alcohol mitigation, rapid CNS recovery after drinking, and mild transaminase elevations when bioavailability-optimized forms are used. DHM carries an excellent safety profile with minimal side effects, and sees use both as a standalone and adjunct to more potent liver agents.

TUDCA wins for potency against real hepatotoxicity—it's the documented choice for oral AAS cycles, marked ALT/AST elevations, cholestasis, gallbladder protection during aggressive cuts or GLP-1 runs, and even off-cycle NAFLD protocols. TUDCA has multidimensional liver protection, better clinical data, and is less sensitive to formulation/bioavailability issues. Side effects are rare, mainly limited to GI upset at high doses.

Pick A or B?

Pick Dihydromyricetin (DHM) if:

  • Acute alcohol mitigation and next-day CNS recovery is the main goal
  • Mild ALT/AST elevation without major cholestatic stress
  • A secondary adjunct to NAC or TUDCA for lighter cycles
  • Looking for a compound with CNS effects (lessening GABAergic intoxication)
  • Research faces cost considerations and needs a lower-priced option for daily support

Pick TUDCA if:

  • 17α-alkylated orals or other hepatotoxic agents are being investigated
  • Significant cholestasis, jaundice, or marked transaminase elevation is documented
  • Gallbladder support is needed during high-fat loss or GLP-1 protocols
  • NAFLD, insulin sensitivity, or metabolic syndrome targets are a focus
  • Maximal effect and fastest liver marker normalization is required, regardless of cost

Where to Buy

Swiss Chems

Swiss Chems

Ships from US

Affiliate link — we may earn a commission at no cost to you.

Use code-10%
BioMogging